These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
116 related articles for article (PubMed ID: 6985379)
21. [Clinical significance of a skin test (SU-PS) for immune responses in patients with gastrointestinal cancer treated with OK-432]. Miyamoto Y; Takeshita M; Izuo M Gan To Kagaku Ryoho; 1986 Oct; 13(11):3229-35. PubMed ID: 3777960 [TBL] [Abstract][Full Text] [Related]
22. [A study on the effectiveness of the adjuvant chemotherapy and immunotherapy and its correlation with cellular immunity]. Sachira ; Onda M; Tokunaga A Nihon Ika Daigaku Zasshi; 1989 Jun; 56(3):308-12. PubMed ID: 2753993 [No Abstract] [Full Text] [Related]
23. [A double blind study of the evaluation of the optimal dose and its frequency in oral administration of OK-432 (Picibanil) by immunological parameters (the 1st report)]. Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S Nihon Gan Chiryo Gakkai Shi; 1990 Apr; 25(4):799-811. PubMed ID: 2196311 [TBL] [Abstract][Full Text] [Related]
24. [Endoscopic preoperative intralesional injection of OK-432 in early gastric cancer]. Yamane T; Sagara Y; Suzuki G; Kasuga M; Sakita M; Fujita Y; Majima S Gan To Kagaku Ryoho; 1984 Apr; 11(4):930-4. PubMed ID: 6721507 [TBL] [Abstract][Full Text] [Related]
25. Pseudomyxoma peritonei: effect of chronic continuous immunotherapy with a streptococcal preparation, OK-432 after surgery. Fukuma K; Matsuura K; Shibata S; Nakahara K; Fujisaki S; Maeyama M Acta Obstet Gynecol Scand; 1986; 65(2):133-7. PubMed ID: 3727940 [TBL] [Abstract][Full Text] [Related]
26. Clinical value of immunochemotherapy with OK-432 or PS-K for stomach cancer patients. Fujimoto S; Takahashi M; Minami T; Ishigami H; Miyazaki M; Itoh K Jpn J Surg; 1979 Sep; 9(3):190-6. PubMed ID: 470251 [TBL] [Abstract][Full Text] [Related]
27. [Tumor growth inhibitory factor (S) produced by lymphocytes in cancer patients with long-term OK-432 therapy]. Katano M Nihon Shokakibyo Gakkai Zasshi; 1986 Sep; 83(9):2088. PubMed ID: 2432298 [No Abstract] [Full Text] [Related]
28. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells]. Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309 [TBL] [Abstract][Full Text] [Related]
29. Augumentation of splenic antitumor immunity by local immunotherapy in gastric cancer patients. Wakasugi T; Takeda T; Monden T; Katsumoto Y; Sakita I; Nagaoka H; Fukunaga M; Tomita N; Kobayashi T; Shiozaki H; Shimano T; Monden M Biotherapy; 1997; 10(2):99-106. PubMed ID: 9373731 [TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of immunochemotherapy with streptococcal preparation "OK-432" on inoperable advanced cancers (author's transl)]. Nio Y; Nitta N; Tanaka A; Ichikawa T; Henmi K Nihon Geka Hokan; 1981 Sep; 50(5):704-10. PubMed ID: 7332399 [No Abstract] [Full Text] [Related]
31. Effect of immunochemotherapy on lymphocyte response of patients with gastrointestinal cancer. Mashiba H; Yoshinaga H; Matsunaga K; Gojobori M; Furusawa M J Surg Oncol; 1979; 12(3):275-9. PubMed ID: 502567 [TBL] [Abstract][Full Text] [Related]
32. The antitumor effects of locally injecting human peripheral blood mononuclear cells treated with OK-432 into the tumor site: the possible role of a tumor growth inhibitory factor (TGIF). Katano M; Mizoguchi T; Yamamoto H; Nakamura M; Matsuo T; Hisatugu T; Kisu T; Yamaoka K; Tokunaga O Jpn J Surg; 1990 Jan; 20(1):76-82. PubMed ID: 2304290 [TBL] [Abstract][Full Text] [Related]
33. Immunological evaluation of a streptococcal preparation (OK-432) in treatment of bladder carcinoma. Kagawa S; Ogura K; Kurokawa K; Uyama K J Urol; 1979 Oct; 122(4):467-70. PubMed ID: 480487 [TBL] [Abstract][Full Text] [Related]
34. [Intratumor injection of OK-432-stimulated peripheral blood mononuclear cells: a significance of mononuclear cell-producing tumor inhibitory factor induced by OK-432]. Mizoguchi T; Katano M; Yamamoto H; Hisatsugu T Nihon Geka Gakkai Zasshi; 1987 Jun; 88(6):794. PubMed ID: 3627102 [No Abstract] [Full Text] [Related]
35. [Effect of endoscopical administration of OK-432 in 4 patients with advanced esophageal or gastric cancer]. Satomi T; Inoue S; Fujita T; Ogawa S; Honda H; Hayashi M Gan No Rinsho; 1989 Mar; 35(4):512-5. PubMed ID: 2541269 [TBL] [Abstract][Full Text] [Related]
36. Effects of intraperitoneal administration of OK-432 for patients with advanced cancer. Toge T; Yamada H; Aratani K; Kameda A; Kuroi K; Hisamatsu K; Hattori T Jpn J Surg; 1985 Jul; 15(4):260-5. PubMed ID: 2932585 [TBL] [Abstract][Full Text] [Related]
37. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group. Noda K; Teshima K; Tekeuti K; Hasegawa K; Inoue K; Yamashita K; Sawaragi I; Nakajima T; Takashima E; Ikeuchi M Gynecol Oncol; 1989 Dec; 35(3):367-72. PubMed ID: 2689304 [TBL] [Abstract][Full Text] [Related]
38. Orally administered streptococcal preparation, OK-432 augments the antitumor immunity of patients with gastric or colorectal cancer. Nio Y; Ohgaki K; Tsuchitani T; Imai S; Shiraishi T; Tobe T Biotherapy; 1990; 2(3):213-22. PubMed ID: 2206774 [TBL] [Abstract][Full Text] [Related]
39. [A case of unresectable advanced gastric cancer with effective treatment by local administration of OK-432 on operation]. Kodama M; Taniguchi T; Furukawa H; Takahashi T; Hara T Gan To Kagaku Ryoho; 1989 Jun; 16(6):2301-3. PubMed ID: 2735772 [TBL] [Abstract][Full Text] [Related]
40. Results of surgery on 6589 gastric cancer patients and immunochemosurgery as the best treatment of advanced gastric cancer. Kim JP; Kwon OJ; Oh ST; Yang HK Ann Surg; 1992 Sep; 216(3):269-78; discussion 278-9. PubMed ID: 1417176 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]